Sugi Predict

Sugi Predict / Compounds / SCHEMBL14128389

SCHEMBL14128389

SCHEMBL14128389

O=C(O)c1cc(Br)c2c(c1Br)CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ AKR1C4 P17516 1/20 0.37
▸ AKR1C3 P42330 1/20 0.37
▸ AKR1C2 P52895 1/20 0.37
▸ AKR1C1 Q04828 1/20 0.37
▸ LCK P06239 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ AMPD1 P23109 1/20 0.34
▸ AMPD3 Q01432 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723114 1.00 SMN1; SMN2 (0.40) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL14236172 0.96 SMN1; SMN2 (0.40) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL14236372 0.83 NPC1 (0.32) MEN1KMT2AALDH1A1ALOX15
SCHEMBL20643007 0.81 SMN1; SMN2 (0.38) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL19330645 0.81 KDM4E (0.42) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL19124079 0.74 GAA (0.42) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL14128277 0.74 SLC6A3 (0.39) MEN1KMT2AALDH1A1TDP1
SCHEMBL31272751 0.72 ALDH1A1 (0.41) SMN1; SMN2MEN1KMT2ATSHRPTPN1
SCHEMBL15610796 0.71 MAPT (0.49) MEN1KMT2AALDH1A1HTTNPSR1
SCHEMBL19124054 0.70 TSHR (0.38) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 — — US disclosed
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER LUPIN LIMITED (IN) 2024-11-07 — — US disclosed
CN-114746411-B Substituted tricyclic compounds 印度鲁宾有限公司 2024-06-25 — — CN disclosed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 — — EP disclosed
EP-4281078-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER Lupin Limited (IN) 2023-11-29 — — EP disclosed
CN-116723843-A Pharmaceutical combination of SOS1 inhibitors for the treatment and/or prevention of cancer 鲁宾有限公司 2023-09-08 — — CN disclosed
US-20230013778-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2023-01-19 — — US disclosed
EP-4065575-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-10-05 — — EP disclosed
WO-2022157629-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER LUPIN LIMITED (IN) 2022-07-28 — — WO disclosed
CN-114746411-A Substituted tricyclic compounds 印度鲁宾有限公司 2022-07-12 — — CN disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES GREEN CROSS CORPORATION (KR) 2014-09-18 — — US disclosed
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES GREEN CROSS CORPORATION (KR) 2014-09-18 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 — — WO disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013778-A1 SUBSTITUTED TRICYCLIC COMPOUNDS SOS1, RSU1, KSR1 SMN1; SMN2 575/4885AKR1C4 1103/4885AKR1C3 1188/4885
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 SMN1; SMN2 4345/4885AKR1C4 528/4885AKR1C3 674/4885
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER NRAS, KRAS, PRMT1 SMN1; SMN2 1418/4885AKR1C4 4558/4885AKR1C3 4601/4885
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES SLC5A2, SLC5A1, SLC10A2 SMN1; SMN2 4674/4885AKR1C4 436/4885AKR1C3 612/4885
US-12435066-B2 Substituted tricyclic compounds SOS1, RSU1, KSR1 SMN1; SMN2 575/4885AKR1C4 1103/4885AKR1C3 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback